共 32 条
[4]
Prospective validatioon obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party
[J].
FRONTIERS IN ONCOLOGY,
2015, 4
[5]
Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients With First-Line Non-Small Cell Lung Cancer Treated With Chemotherapy With or Without Bevacizumab
[J].
JOURNAL OF CLINICAL PHARMACOLOGY,
2014, 54 (03)
:253-257
[6]
Gjomarkaj M, 1997, EUR RESPIR J, V10, P592
[7]
Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial
[J].
CLINICAL LUNG CANCER,
2011, 12 (06)
:407-411